Sanofi【1SAN】銘柄情報

Sanofi (1SAN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

( - )

買値

売値

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

2,520,655 €

発行済株式数

1,200,220,109

配当利回り

(5.35%)

PER

19.32

1 株当たり利益 (EPS)

6.2

歳入

47.35B

純利益

7.56B

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respi... Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.sanofi.com

本社

Paris, France

設立

1994

Sanofi is listed in the Healthcare sector of the イタリア証券取引所 with ticker 1SAN. The last closing price for Sanofi was -. Over the last year, Sanofi shares have traded in a share price range of 0.00 € to 0.00 €.

Sanofi currently has 1,200,220,109 shares in issue. Sanofi has a price to earnings ratio (PE ratio) of 19.32.

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Sanofi: Information concerning the total number of voting rights and shares – May 2026 Information concerning the total number of voting rights...

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mai 2026

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mai 2026 Informations relatives au nombre total de droits...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1...

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment...

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Sanofi...

Communiqué de presse : Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire démyélinisante chronique

Communiqué de presse : Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire...

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sanofi’s...

Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable

Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un...

Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié

Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié Sanofi lance son plan mondial 2026 d’actionnariat salarié ...

Press Release: Sanofi launches 2026 global employee stock purchase plan

Press Release: Sanofi launches 2026 global employee stock purchase plan Sanofi launches 2026 global employee stock purchase plan Paris, June 4...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

1SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 0.00 €

How many Sanofi shares are in issue?

Sanofi has 1,200,220,109 shares in issue

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 0.00 € to 0.00 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 19.32

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 1.94

What is the registered address of Sanofi?

The registered address for Sanofi is 46, avenue de la Grande ArmEe, Paris, Ile-de-France, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the Pharmaceuticals sector

rjack18 1分前

Agreed, they have it locked up now. Any volume and back to 003

GNIS

THEBEASTMUGABI 2分前

STFU !

IONQ

Jmetrish 2分前

Our shared reflection:
Many of us recall that the momentum killer for Veemost was severe regulatory brick walls of FINRA. The app to change the company’s name, update the CUSIP number, and swap the ticker from GDVM to VMST took 2 years because of historical SEC reporting gaps dating back to 2

VMST

ssc 3分前

Are you really suggesting "A rights offering that distributes to existing shareholders the right to buy additional shares, usually at a discount". A rights offering with the current bid price at $.0006? A rights offering where even if every shareholder participated at the 100% level with a discoun

DBMM

Kentucky123 3分前

Agree with everything you say about Doc328. He has been insightful and willing to share for the benefit of all. I wish he had been wrong because I did not pay enough attention. He says there is no reason to invest currently.
My father was sarcastic and it was hurtful. Not a fan. I have

AVXL

teddibear 3分前

Pineapple Express Cannabis Co. (doing business as Autonomous AI Holdings) reports through the SEC Edgar system but faces ongoing structural delinquency risks:
Form 8-K Current Report: Filed on April 17, 2026, to legally document its pivot away from cannabis operations into AI executive softwa

WNBDD

BBANBOB 3分前

YEPPERS 5/1 buys over sells and we are down when yesterday the sells outpaced the buys and we were up if I remember correctly

TELL ME THIS AIN BEING MANIPULATED

RDGL

boston127 3分前

I have seen the graphs. They show

that the company has lost 99% of its value over the past 3 years. That is why we are buying so low, as this is a much better company now. Look at the 2026 forecasts for revenue. Look at the revenue numbers for 2025.

GPUS

November61 3分前

WOW. Saw the same in Italy for getting the olives.

Shaking the tree Big Time.
Not over yet.
Yesterday volume before lunch time.

SRXH

vlispxpert 3分前

MSTR zone getting closer, I'm going to focus more on MSTX now, I got plenty of MSTR...will add some MSTR under $108, but plan on doubling MSTX...come to papa!

MSTR MSTX

weedtrader420 4分前

A crack below 60 try 40 the new Fed wants to raise rates oh my Lord. trump put him in there to lower rates. another one of Trump‘s feds down the drain.

BTCUSD

rosemountbomber 4分前

There might be more value in discussing the topic at hand rather than where someone is sitting.

If everything is so fantastic and the future so bright, why are we sitting below 80 cents pre-split?

AMRN

Whalatane 4分前

Wizard Interesting post ...thx . I'll defer to Ernie on positioning pre Russell Inclusion .
I think UNCY is selling stock since the notice of effectiveness re $50m being added to their ATM ...to raise cash .
My guess is they will raise about $10m this week and the same next week .

UNCY

tdbowieknife 4分前

One of the steps would be to upgrade the electrical service. A fusion reactor of the type AMFN describes would require multi-megawatt electrical service capacity, far beyond what any small industrial building provides. Typically, 5–10× more than standard industrial service. Installing that level of

AMFN

The Truth Hurts 4分前

Its been like this for over a week at least...

RITE

BigBadWolf 5分前

1. The "Independent Advisor" Cloak (No Skin in the Game)
The pumper claims this is a "deeply defensive operational perimeter" and an elite "scientific leadership team."
The Reality: Notice the exact title given in this morning's PR: "Independent Scientific and Strategic Advisor." Dr. D

AMFN

tnyellowtomcat 5分前

I would think so, and perhaps that in part explains the rise in LQMT stock from .04 to .19.

IMHO - Tomcat

LQMT

powercrush86 5分前

good long term buy here IMO

YUM

Golden Cross 5分前

American Fusion Inc. Arrives to Accept Delivery of 5MW Pre-Production Texatron™ Fusion Engine™
https://finance.yahoo.com/energy/articles/american-fusion-inc-otc-amfn-120000649.html

AMFN

getmoreshares 6分前

https://pbs.twimg.com/media/HLDl7cAaoAAHOER?format=png&name=small

Runners123 6分前

ATPC low float but 60plus shorted yesterday and the have been shorting as they covered

ATPC

getmoreshares 7分前

https://pbs.twimg.com/media/HLDl7cAaoAAHOER?format=png&name=small

Clayton Bigsbee 7分前

You're 60 and whining on a public forum.

FBEC

teddibear 7分前

PNXP

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sanofi (1SAN)